COAG Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
30.0M
+15.0%
26.1M
R&D
24.6M
+21.2%
20.3M
SG&A
5.1M
-10.9%
5.7M
Operating Income
-29995000
-15.0%
-26079000
EBITDA
-29920000
-15.1%
-26004000
Net Income
-27304000
-13.1%
-24150000
EPS (Basic)
$-0.58
+27.5%
$-0.80
EPS (Diluted)
$-0.58
+27.5%
$-0.80
Shares (Diluted)
46.7M
+55.1%
30.1M
Hemab Therapeutics (COAG) — Financials